Hydroxyurea Medak

Acute lymphoblastic leukemia in children, osteomyelofibrosis, erythremia, thrombocytosis in the myeloproliferative syndrome program, lymphogranulomatosis, melanoma, head and neck tumors when radical surgical treatment or radiation therapy is not possible, metastases of breast and stomach cancer, colon cancer, prostate cancer, lung cancer , ovarian cancer, uterine chorionic carcinoma, cervical cancer (to increase the effectiveness of radiation therapy).

Hydroxycarbamide Medak (international name - Hydroxycarbamide) is a synthetic antitumor agent of various groups. Manufactured in Germany by Medak GmbH. Dosage form: 500 mg capsules, active ingredient: Hydroxycarbamide.

The drug is used for the treatment of acute and chronic myeloid leukemia, relapses of acute lymphoblastic leukemia in children, osteomyelofibrosis, erythremia, thrombocytosis in the myeloproliferative syndrome program, lymphogranulomatosis, melanoma, head and neck tumors when radical surgical treatment or radiation therapy is not possible, metastases of breast and stomach cancer, colon cancer, prostate cancer, lung cancer, ovarian cancer, uterine chorionic carcinoma, cervical cancer (to increase the effectiveness of radiation therapy).

Contraindications to the use of Medak Hydroxycarbamide: hypersensitivity, acute renal or liver failure, thrombocytopenia, severe leukopenia, profound anemia, pregnancy, breastfeeding.

When using the drug, side effects may be observed, such as myelosuppression (as the first sign of leukopenia, pancytopenia), dyspeptic disorders, stomatitis, fever, headaches, dizziness, disorientation, hallucinations, interstitial nephritis, hyperuricemia, increased levels of transaminases in the blood serum, alopecia, facial erythema, maculopapular rash; rarely - diffuse infiltrative lung lesions, allergic skin reactions.

Hydroxycarbamide Medak may interact with other medicines. It enhances the effect of cytarabine and increases the myelotoxicity of blood depressants such as warfarin and acetylsalicylic acid. In addition, the drug may increase the toxicity of cyclophosphamide and methotrexate, as well as increase the level of phenytoin in the blood.

Before starting the use of Hydroxycarbamide Medak, it is necessary to conduct a complete examination of the patient, including an assessment of renal and liver function, the hematopoietic system and electrolyte balance. Treatment is carried out under the supervision of a specialist and can be adjusted depending on the effectiveness and tolerability of the drug.

You cannot start or stop taking Medak Hydroxycarbamide on your own without consulting a doctor. Before using any medicines, you should read the instructions for use and consult your doctor.